These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35677507)

  • 41. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC.
    Shingina A; DeWitt PE; Dodge JL; Biggins SW; Gralla J; Sprague D; Bambha K
    Transplantation; 2019 Jan; 103(1):140-148. PubMed ID: 30451739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand.
    Calzadilla-Bertot L; Jeffrey GP; Jacques B; McCaughan G; Crawford M; Angus P; Jones R; Gane E; Munn S; Macdonald G; Fawcett J; Wigg A; Chen J; Fink M; Adams LA
    Liver Transpl; 2019 Jan; 25(1):25-34. PubMed ID: 30609187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
    Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic.
    Agopian VG; Kaldas FM; Hong JC; Whittaker M; Holt C; Rana A; Zarrinpar A; Petrowsky H; Farmer D; Yersiz H; Xia V; Hiatt JR; Busuttil RW
    Ann Surg; 2012 Oct; 256(4):624-33. PubMed ID: 22964732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
    Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
    JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C.
    Henson JB; Wilder JM; Kappus MR; Barbas AS; Moylan CA; Niedzwiecki D; Muir AJ; Berg CL; Patel YA
    Transplantation; 2020 Jun; 104(6):e164-e173. PubMed ID: 32150036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.
    Yoon JS; Lee HY; Chung SW; Kim SW; Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim H; Yoon JH; Kim YJ
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1960-1968. PubMed ID: 32128882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.
    Shima T; Uto H; Ueki K; Takamura T; Kohgo Y; Kawata S; Yasui K; Park H; Nakamura N; Nakatou T; Tanaka N; Umemura A; Mizuno M; Tanaka J; Okanoue T
    J Gastroenterol; 2013 Apr; 48(4):515-25. PubMed ID: 22911170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis.
    Ahmed O; Liu L; Gayed A; Baadh A; Patel M; Tasse J; Turba U; Arslan B
    J Clin Exp Hepatol; 2019; 9(1):50-55. PubMed ID: 30765939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Malik SM; Gupte PA; de Vera ME; Ahmad J
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):800-6. PubMed ID: 19281869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation.
    Quillin RC; Wilson GC; Sutton JM; Hanseman DJ; Paterno F; Cuffy MC; Paquette IM; Diwan TS; Woodle ES; Abbott DE; Shah SA
    Surgery; 2014 Oct; 156(4):1049-56. PubMed ID: 25239365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants.
    Nayak NC; Jain D; Vasdev N; Gulwani H; Saigal S; Soin A
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1199-208. PubMed ID: 22751227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.
    Lim N; Singh D; Jackson S; Lake JR
    Gastrointest Tumors; 2020 Oct; 7(4):134-143. PubMed ID: 33173777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.